Neurofibromatosis - Pipeline Review, Q2 2011 - Bharatbook added a new report on "Neurofibromatosis - Pipeline Review, Q2 2011', provides an overview of the Neurofibromatosis therapeutic pipeline."
Neurofibromatosis - Pipeline Review, Q2 2011', provides an overview of the
Neurofibromatosis therapeutic pipeline. This report provides information on the
therapeutic development for Neurofibromatosis, complete with latest updates, and
special features on late-stage and discontinued projects. It also reviews key
players involved in the therapeutic development for Neurofibromatosis.
'Neurofibromatosis - Pipeline Review, Q2 2011' is built using data and
information sourced from Global Markets Direct’s proprietary databases,
Company/University websites, SEC filings, investor presentations and featured
press releases from company/university sites and industry-specific third party
sources, put together by Global Markets Direct’s team.
{http://www.bharatbook.com/detail.asp?id=199143&rt=Neurofibromatosis-Pipeline-Review-Q2-2011.html}
- A snapshot of the global therapeutic scenario for Neurofibromatosis.
- A review of the Neurofibromatosis products under development by companies and
universities/research institutes based on information derived from company and
industry-specific sources.
- Coverage of products based on various stages of development ranging from
discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined
therapeutics.
- Coverage of the Neurofibromatosis pipeline on the basis of therapeutic class,
route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product
description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under
development for Neurofibromatosis.
- Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most
promising pipeline.
- Devise corrective measures for pipeline projects by understanding
Neurofibromatosis pipeline depth and focus of Neurofibromatosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand
business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline.
Disclaimer: Dime-Co.Com is an online information article and video article network. All articles, video articles, comments, and other features herein are for informational purposes only and are provided "as is" without warranties, representations or guarantees of any kind. The views and opinions expressed in an article, comments, links or blogs are the author's own, and not necessarily those of dime-co.com's owners. For full disclaimer, please read our TOS.